Clinical trial · Observational
Evaluation of Serum Preptin Levels in Patients With Polycystic Ovary Syndrome
Evaluation of Serum Preptin Levels and Their Relationship With Insulin Resistance in Patients With Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is strongly associated with insulin resistance and metabolic dysfunction. Preptin is a pancreatic peptide co-secreted with insulin and has been implicated in glucose metabolism and insulin resistance. However, limited data exist regarding serum preptin levels in patients with PCOS. The aim of this study is to evaluate serum preptin levels in women diagnosed with PCOS and to investigate the relationship between preptin levels and insulin resistance parameters.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Insulin Resistance | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome (PCOS) | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- PCOS Group
- description
- Patients diagnosed with PCOS according to the Rotterdam criteria.
- label
- Control Group
- description
- Women presenting with similar complaints but not meeting Rotterdam diagnostic criteria for PCOS.
Primary outcomes (1)
- measure
- Serum Preptin Concentration
- timeFrame
- Baseline
- description
- Serum preptin concentration measured by enzyme-linked immunosorbent assay (ELISA) and expressed in pg/mL.
Secondary outcomes (1)
- measure
- Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Female participants aged 18-45 years * Diagnosis of PCOS according to Rotterdam criteria * BMI \<30 kg/m² * No PCOS treatment during the previous 6 months * Not pregnant or breastfeeding * No active infection * No rheumatologic or inflammatory disease * No chronic systemic disease * Written informed consent Exclusion Criteria: * Age \<18 years or \>45 years * Pregnancy or breastfeeding * PCOS treatment within the previous 6 months * Active infection * Rheumatologic or inflammatory disease * Hypertension * Diabetes mellitus * Chronic kidney disease * Refusal to participate
References
Publications (0)
Data not yet available